Alcazar-Navarrete, BernardinoManuel Diaz-Lopez, JoseGarcia-Flores, PaulaOrtega-Antelo, MarinaAguilar-Cruz, IvanRuiz-Rodriguez, OliverioSantiago-Diaz, PabloRomero Palacios, Pedro Jose2025-01-072025-01-072022-08-010300-2896https://hdl.handle.net/10668/24872Introduction: Type 2 (T2) biomarkers such as blood eosinophil count (BEC) and FeNO have been related to a higher risk of exacerbations in COPD. It is unknown whether combining these biomarkers could be useful in forecasting COPD exacerbations. Methods: COPD patients were enrolled in this prospective, multicenter, observational study and followed up for 1 year, during which BEC were analysed at baseline (V0) while FeNO analyses were performed at baseline (V0), 6 months (V1) and 12 months (V2). The risk of moderate or severe exacerbation during follow up was assessed by Cox regression analysis, and the predictive capacity of both measurements was assessed by ROC curves and the DeLong test. Statistical significance was assumed at PenCOPDType 2 inflammationBiomarkersFe NOEosinophilBlood eosinophilsMortalityRiskresearch article3531253510.1016/j.arbres.2021.11.0061579-2129862248000006